1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Pfizer Deal Will Dramatically Reshape Mylan’s Model

 
• By Dave Wallace

Following the announcement of a merger between Mylan and Pfizer’s Upjohn, the top executive team that will take charge of the combination has set out its vision for the company.

Potter
Merging with Upjohn will reshape Mylan’s business model • Source: Shutterstock

Merging with Pfizer’s Upjohn off-patent unit will dramatically remould Mylan’s business model, according to the leadership team of the combined company that is expected to be operational from mid-2020.

The deal – announced on 29 July – will see the firms combined in an all-stock transaction under a ‘reverse...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Byooviz US Launch Slated For 2026 As Harrow Touts Immediate Uptake Potential

 
• By Dean Rudge

Harrow is taking aim at launching new partner Samsung Bioepis’ Byooviz biosimilar to Lucentis in 2026.

Fresenius Kabi Pharma Bounces Back In Q2 With Strong US and Europe Volumes

 
• By Dean Rudge

Fresenius Kabi’s IV drugs and fluids Pharma division rebounded in Q2, led by strong US and European volumes, especially in infusion therapies. Biopharma revenue rose by 26% to €190m, up one-third in constant currencies, driven by tocilizumab biosimilar ramp-up in Europe and the US.

Intas Expands Its Plasma Business With A European Acquisition

 
• By Urtė Fultinavičiūtė

Building on its decade-old plasma division in India, Intas and its subsidiary Accord signed an agreement to acquire one of Europe's largest plasma fractionators Prothya Biosolutions.